OptiNose Stock (NASDAQ:OPTN), Trade Ideas

OptiNose

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

Caterpillar - logo

ACON

AIRE

ATNI

BMRN

BNAI

BPTS

BRFH

BRKL

CDTX

CSSE

CYCC

ESGL

FCFS

HRYU

HUIZ

ILAG

JAKK

OPTN

ORGO

PCSA

POAI

PTSI

SGBX

SNBR

SPCB

STRA

ULBI

ZAPP

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

MLGO

PHVS

SERA

YEXT

U.S. stocks traded mixed toward the end of trading on Wednesday.

The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&amp;P 500 also fell, dropping, 0.05% to 4,564.73.

Gold Moves Higher; Campbell Soup Earnings Top Expectations

Movers

AAOI

ALLR

ARVN

ASAN

ASPN

AVAV

BCRX

CANO

CHSN

CJET

CLIN

CZOO

FLNC

GBNH

JNVR

LEJU

LGHL

LOVE

MESA

NRSN

NVNI

PHIO

PLAY

POWL

RELI

RENT

SFIX

SOAR

TGTX

WBUY

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

OptiNose Inc

Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares are trading higher Tuesday amid a rally in meme stocks after retail investor Roaring Kitty made a <a href="https://www.benzinga.com/news/24/05/38819873/sony-group-posts-upbeat-earnings-joins-gamestop-paysafe-and-other-big-stocks-moving-higher-on-tuesda">return to social media.&nbsp;</a>
The Details:
The return of Roaring Kitty to <a href="https://www.benzinga.com/news/24/05/38795608/gamestop-leads-roaring-rally-whats-going-on-with-meme-stocks">social media</a> has triggered a meme stock resurgence which began with shares of GameStop and AMC Entertainment and has extended to other stocks with high short-interest, including Beyond Meat.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, 36.87% of Beyond Meat's float is being sold short.&nbsp;
In June of 2021, Beyond Meat had a market capitalization of just under $10 billion which has dropped to approximately $516 million at present. The stock has fallen nearly 90% since 2021.&nbsp;
Beyond Meat shares are moving on heavy trading volume amid the rally with more than 11.45 million shares already traded in Tuesday's session, compared to the stock&#8217;s 100-day average of 3.655 million shares.
Related News: <a href="https://www.benzinga.com/news/24/05/38797005/whats-going-on-with-rivians-stock">What&#8217;s Going On With Rivian&#8217;s Stock?</a>
<h2 class="wp-block-heading">Should I Sell My BYND Stock? </h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Beyond Meat have lost 1.7% year to date. This compares to the average annual return of -57.67%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Beyond Meat stock currently has an RSI of 62.13, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
BYND Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Beyond Meat shares are up 6.85% at $8.50 at the time of publication Tuesday.
Image: Courtesy of Beyond Meat, Inc.

BYND

Why Beyond Meat's Stock Is Roaring Higher

MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.13 by 7.69 percent. This is a 180 percent increase over earnings of $0.05 per share from the same period last year. The company reported $827.00 thousand in sales this quarter. This is a 46.63 percent increase over sales of $564.00 thousand the same period last year.

Earnings Beats

MAG Silver Q1 EPS $0.14 Beats $0.13 Estimate, Sales $827.00K Up From $564.00K YoY

WIIM

RKDA

Arcadia Biosciences shares are trading higher after the company announced the sale of its non-GMO Resistant Starch Durum Wheat trait.

Jefferies&nbsp;analyst Kaumil&nbsp;Gajrawala upgraded&nbsp;Boston Beer Company, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) to Buy from Hold,&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SAM/analyst-ratings" rel="noreferrer noopener">raising the price forecast to $360 from $335.</a>
Boston Beer has gone through several boom-bust cycles, but over time, value was created with higher highs and higher lows, the analyst writes.
The&nbsp;company&#8217;s beer and cider brands continue to decline, in line with the category. Collectively these brands are ~28%, Gajrawala notes.&nbsp;
However, reduced SKU complexity and refocused marketing could stabilize the business as category trends moderate. Given their relative size to Twisted/Truly, their headwinds should have minimal effect on total company trends&nbsp;going forward.
In addition, easing supply chain costs, higher in-house production, and efficiency measures support gross margin returning to normalized levels (high 40s %) over the medium term.&nbsp;
A clean balance sheet (no debt) and record cash levels increase the potential for capital returns if new initiatives do not gain traction, according to the analyst.
Per Gajrawala,&nbsp;with Truly trends stabilizing and Twisted continuing its recent growth trends, the company should return to volume growth for the first time since 2021.
Overall, the analyst raised the company&#8217;s full-year 2024 sales/EBITDA outlook by +1% and +3%,&nbsp;respectively.
The analyst applauds the company&#8217;s margin outlook and multiple expansions on&nbsp;return to volume&nbsp;growth and decreased volatility.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SAM stock has lost 9% in the past year.&nbsp;
Gajrawala&nbsp;reiterated the Buy rating on&nbsp;Constellation Brands, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), l<a target="_blank" href="https://www.benzinga.com/quote/STZ/analyst-ratings" rel="noreferrer noopener">owering&nbsp;the price target to $311 from $314.</a>
The analyst lowered the first quarter and FY25 sales outlook by -1% and &lt;-1% and EBITDA by -3% and -1%, respectively, given recent weakness.&nbsp;However, distributors remain bullish on Constellation. The analyst&#8217;s survey supports ~7%-9% org sales growth in their beer business.
Gajrawala reiterated&nbsp;Hold&nbsp;rating&nbsp;on&nbsp;Molson Coors Beverage Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>),&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/TAP/analyst-ratings" rel="noreferrer noopener">with&nbsp;forecast&nbsp;of&nbsp;$62.00.</a>
The analyst lowered CY24 sales &lt;-1% and EBITDA by -1%, given confirmed lower space gains, ABI momentum, and margin deleverage.
Price Action: TAP shares are trading lower by 1.45% to $57.89 at last check Tuesday, while STZ shares are trading lower by 2.2% to $253.07 and SAM shares are trading higher by 0.29% to $284.64.
Photo via Shutterstock

Analyst Color

Equities

Upgrades

Price Target

Reiteration

Analyst Ratings

General

Boston Beer Company Gets A Spicy Buy Upgrade From Analyst Amid Other Beer Brands - Read Why

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon Solar Technologies shares are trading higher. The stock may be gaining amid strength in high-short interest stocks.

Macro Economic Events

Economics

National Transportation Safety Board Releases Preliminary Report On Baltimore Bridge Collapse

Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares are trading higher Tuesday amid a rally in &#8216;meme stocks&#8217; and high-short interest stocks after Roaring Kitty <a href="https://www.benzinga.com/news/24/05/38795608/gamestop-leads-roaring-rally-whats-going-on-with-meme-stocks">returned to social media.</a>
The Details:
BofA Securities<a href="https://www.benzinga.com/quote/HTZ/analyst-ratings"> reiterated</a> its rating of Underperform and price target of $3 on Hertz Global Tuesday amidst rising costs and liquidity concerns.&nbsp; BofA noted the company's inability to effectively match supply with demand via its fleeting and de-fleeting of vehicles and weaker used vehicle pricing which could keep Hertz's fleet costs elevated.&nbsp;
The firm also sees softer macro-economic conditions potentially leading to weakness in rental days and transactions for the company.&nbsp;&nbsp;
Hertz shares are moving higher on heavy volume Tuesday as the return of Roaring Kitty has led to a rally in high-short interest stocks and meme stocks. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, 19.42% of Hertz shares are being sold short and more than 11.9 million shares have already been traded in the session. &nbsp;
Related News: <a href="https://www.benzinga.com/news/24/05/38797005/whats-going-on-with-rivians-stock">What&#8217;s Going On With Rivian&#8217;s Stock?</a>
<h2 class="wp-block-heading">HTZ Stock Prediction 2024: </h2>
Hertz Global Holdings&#8217; revenue growth in fiscal year 2023 was 7.9%, reflecting the influence of various factors including the macroeconomic environment, demand for its products and services, and its position relative to competitors. This growth is a critical indicator for investors assessing the company&#8217;s future prospects.
Some macro factors that could impact the company's performance in the next year include higher interest rates, progress on reeling in inflation and labor market strength. The Fed's benchmark rate is currently at 5.33%, while PPI recently came in at 0.5%, growing 2.2% from last year. The unemployment rate was most recently reported as 3.9%.
An investor should pay attention to economic conditions to decide whether they think the macro environment is positive or negative for Hertz Global Holdings stock. For real time economic data and breaking market updates, <a href="https://pro.benzinga.com/">check out Benzinga Pro. Try it for free.</a>
How does this stack up against Hertz Global Holdings's peers?
Investors may also want to analyze a stock in comparison to companies with similar products or in similar industries. Hertz Global Holdings operates in the Industrials sector. The stock has experienced average annual growth of -38.59% compared to the -27.4% average of its peer companies. This is below the broader sector movement of Hertz Global Holdings.
HTZ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Hertz Global shares are up 9.05% at $5.96 at the time of publication Tuesday.
Image: Shutterstock

What's Going On With Hertz Stock Today?

Barstool Sports founder and stock trader Dave Portnoy is back on meme stocks again with an investment in GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) and AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) as shares rally and <a href="https://www.benzinga.com/markets/equities/24/05/38787490/gamestop-shares-surge-as-roaring-kitty-resurfaces-after-3-year-silence">see increased interest.</a>
What Happened: Similar to a rally in the price of GameStop and AMC as <a href="https://www.benzinga.com/general/gaming/23/01/30412695/gamestop-short-squeeze-anniversary-a-look-back-at-david-vs-goliath-battle-and-whats-next">high short interest stocks in 2021, </a>the stocks have returned with a vengeance in May 2024 and Portnoy is ready.
Portnoy shared in a series of videos his return to meme stocks and his commentary on the return of Roaring Kitty, aka Keith Gill, to social media.
"I can't miss it," Portnoy <a href="https://www.instagram.com/stories/stoolpresidente/3367818057442540013/">said </a>of the return of meme stocks. "I got to be involved."
Portnoy <a href="https://twitter.com/stoolpresidente/status/1790374692567625963">shared </a>that he bought $250,000 each in GameStop and AMC on Monday.
"I wish I bought more."
Portnoy shared that in pre-market trading Tuesday he was up close to $700,000 with AMC and GameStop each up over 100% from their Monday closing price.
"This thing is going to the moon."
In a video, Portnoy <a href="https://twitter.com/stoolpresidente/status/1790116428089115091">said </a>his buy-in price was $5.20 per share for AMC and $30.40 for GameStop.
"Let's squeeze this s&#x2A;&#x2A;&#x2A; to the moon."
Related Link: <a href="https://www.benzinga.com/general/education/24/05/38793704/who-is-roaring-kitty-why-does-his-return-to-social-media-matter-for-gamestop-stock">Who Is Roaring Kitty? Why Does His Return To Social Media Matter For GameStop Stock?</a>
Why It's Important: Portnoy was one of the key figures in the rally of meme stocks in 2021 as his "Davey Day Trading" stock trading program highlighted stocks with high short interest and that were mooning.
On Tuesday, Portnoy cautioned that he had out points and told viewers not to diamond hand the stocks and hold forever, a valuable lesson he may have learned from the previous meme stock rally.
"At some point you need to realize some gains," Portnoy said.
Portnoy said he was hoping to make a million dollars on his trade and would consider selling the stock and buying back in several times.
In 2021, Portnoy lost money on his meme stock trades and placed a portion of the blame on Robinhood CEO Vlad Tenev for the stock brokerage halting shares and not allowing people to sell during certain times.
"I have officially sold all my meme stocks. I lost 700k ish. Vlad and company stole it from me and should be in jail," Portnoy <a href="https://twitter.com/stoolpresidente/status/1356618475234557956">tweeted </a>on Feb. 2, 2021.
Portnoy criticized the trading halts of GameStop and AMC that occurred on Tuesday during his <a href="https://rumble.com/v4v2ewe-davey-day-trader-may-14-2024.html">livestream</a>.
The Barstool Sports founder <a href="https://www.benzinga.com/government/21/01/19383244/dave-portnoy-joins-benzingas-power-hour-to-talk-gamestop-robinhood-and-more">joined Benzinga's "Power Hour"</a> back in 2021 to discuss investors not being able to buy and sell stocks after the huge increase in the value of GameStop stock.
"People need to go to jail," Portnoy <a href="https://www.youtube.com/watch?v=oKd_pGq7FwE">said </a>at the time. "Robinhood needs to know this is the end of their company."
GME, AMC Price Action: GameStop shares are up 52% to $46.15 on Tuesday, setting new 52-week highs of $64.82 earlier in the trading session.
AMC shares are up 47% to $7.62 on Tuesday and hit a high of $11.88 during the day's trading session.
Read Next: <a href="https://www.benzinga.com/general/sports-betting/24/02/37239149/exclusive-draftkings-partnership-with-barstool-sports-getting-the-band-together-ceo-says-h">EXCLUSIVE: DraftKings Partnership With Barstool Sports &#8216;Getting The Band Together,&#8217; CEO Says — How New Deal, Jackpocket Acquisition Can Power Growth</a>
Photo by <a href="https://www.flickr.com/people/58980992@N03" target="_blank" rel="noreferrer noopener">Zach Catanzareti Photo</a> via Wikimedia.

Dave Portnoy Buys $250K GameStop Stock, $250K AMC Stock: 'I Wish I Bought More'

Have you evaluated the performance of Gen Digital&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gen#NASDAQ">GEN</a>) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this security software maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
The global economy today is deeply interlinked, making a company&#39;s engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm&#39;s potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While delving into GEN&#39;s performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.
The company&#39;s total revenue for the quarter amounted to $967 million, showing rise of 2.1%. We will now explore the breakdown of GEN&#39;s overseas revenue to assess the impact of its international operations.
Unveiling Trends in GEN&#39;s International Revenues
EMEA accounted for 24.2% of the company&#39;s total revenue during the quarter, translating to $234 million. Revenues from this region represented a surprise of +0.27%, with Wall Street analysts collectively expecting $233.36 million. When compared to the preceding quarter and the same quarter in the previous year, EMEA contributed $230 million (24.1%) and $225 million (23.8%) to the total revenue, respectively.
Of the total revenue, $97 million came from APJ during the last fiscal quarter, accounting for 10.0%. This represented a surprise of -3.01% as analysts had expected the region to contribute $100.01 million to the total revenue. In comparison, the region contributed $100 million, or 10.5%, and $99 million, or 10.5%, to total revenue in the previous and year-ago quarters, respectively.
Prospective Revenues in International Markets
It is projected by analysts on Wall Street that Gen Digital will post revenues of $968.37 million for the ongoing fiscal quarter, an increase of 2.4% from the year-ago quarter. The expected contributions from EMEA and APJ to this revenue are 24.6% and 10.4%, translating into $238.25 million and $100.62 million, respectively.
For the full year, a total revenue of $3.91 billion is expected for the company, reflecting an increase of 2.2% from the year before. The revenues from EMEA and APJ are expected to make up 25.1% and 10.7% of this total, corresponding to $980.33 million and $417.38 million respectively.
Wrapping Up
Relying on global markets for revenues presents both prospects and challenges for Gen Digital. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company&#39;s future outlook.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It&#39;s important to note, however, that a range of additional variables, like a company&#39;s local market status, also play a crucial role in shaping these forecasts.
Emphasizing a company&#39;s shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock&#39;s price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock&#39;s price.
Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.
Gen Digital currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Exploring Recent Trends in Gen Digital&#39;s Stock Price
The stock has increased by 16.5% over the past month compared to the 2% rise of the Zacks S&amp;P 500 composite. Meanwhile, the Zacks Business Services sector, which includes Gen Digital, has increased 0.6% during this time frame. Over the past three months, the company&#39;s shares have experienced a gain of 12.4% relative to the S&amp;P 500&#39;s 5.8% increase. Throughout this period, the sector overall has witnessed a 1.4% increase.
<a href="https://www.zacks.com/stock/news/2273557/investing-in-gen-digital-gen-don-t-miss-assessing-its-international-revenue-trends?cid=CS-BENZ-FT-fundamental_analysis|nfm_international_revenues-2273557">To read this article on Zacks.com click here.</a>

Tech

Investing in Gen Digital? Don't Miss Assessing Its International Revenue Trends

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 13.37% since its last report. The company recently reported that it has 975 thousand shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715715024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About West Pharmaceutical Servs?

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 10 years by 5.04% on an annualized basis producing an average annual return of 15.84%. Currently, Centene has a market capitalization of $41.39 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 10 years ago, it would be worth $4,347.07 today based on a price of $77.55 for CNC at the time of writing.
<h3>Centene's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715715021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 10 Years

VF's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) short percent of float has risen 9.34% since its last report. The company recently reported that it has 37.21 million shares sold short, which is 10.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>VF Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715715018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for VF has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing VF's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, VF's peer group average for short interest as a percentage of float is 8.47%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into VF's Recent Short Interest

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) has outperformed the market over the past 15 years by 16.93% on an annualized basis producing an average annual return of 29.33%. Currently, Saia has a market capitalization of $10.78 billion. 
Buying $100 In SAIA: If an investor had bought $100 of SAIA stock 15 years ago, it would be worth $4,656.19 today based on a price of $406.33 for SAIA at the time of writing.
<h3>Saia's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715715015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAIA

$100 Invested In This Stock 15 Years Ago Would Be Worth $4,700 Today

Blink Charging's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NYSE">BLNK</a>) short percent of float has fallen 3.96% since its last report. The company recently reported that it has 21.33 million shares sold short, which is 23.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Blink Charging Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715715012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blink Charging has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Blink Charging's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Blink Charging's peer group average for short interest as a percentage of float is 9.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BLNK

(BLNK) - Analyzing Blink Charging's Short Interest

This week&#8217;s inflation data releases could trigger <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38824874/did-producer-price-inflation-data-cause-bitcoin-to-slide-2">a volatile few days</a> for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), according to a new report by 10x Research, a firm specializing in institutional crypto research.
What Happened: &#8220;Traders expect a +/-6% move for Bitcoin by the end of this week,&#8221; <a href="https://mail.10xresearch.co/p/weeks-inflation-data-means-bitcoins?utm_source=mail.10xresearch.co&amp;utm_medium=newsletter&amp;utm_campaign=what-this-week-s-inflation-data-means-for-your-bitcoins">says</a> the report&#8217;s author, Markus Thielen.
However, Thielen suggests a significant price swing may not be inevitable. 
&#8220;Implied volatility is not expensive,&#8221; he notes, meaning investors aren&#8217;t pricing in a dramatic move based on inflation figures.
Technically, Bitcoin is currently hovering around the $60,800 to $61,400 support level. &#8220;A break below this level could trigger lower prices,&#8221; warns Thielen. 
He adds that the average entry price for Bitcoin ETFs sits at around $57,000, so a drop below $60,000 &#8220;could cause anxiety for those investors.&#8221;
The report highlights a potential correlation between Bitcoin price movements and recent inflation data. &#8220;Bitcoin sold off after each of the last two CPI/PPI data points,&#8221; Thielen observes. 
These sell-offs were around 12-14% each, but ultimately halted by dovish comments from Federal Reserve Chair Jerome Powell.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read:<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38821194/wisconsin-invests-nearly-100m-in-blackrocks-spot-bitcoin-etf"> Wisconsin Invests Nearly $100M In BlackRock&#8217;s Spot Bitcoin ETF</a>
Why It Matters: While 10x Research&#8217;s inflation model predicts a slightly lower CPI number for Wednesday, it also suggests inflation will remain elevated in the near future.
&#8220;Wall Street estimates are at +0.3% MoM and +3.6% YoY (vs. 3.5% previously),&#8221; the report states.
&#8220;Our model leads by two months, and it appears that the model got the turning points right in the past year,&#8221; Thielen continues. 
&#8220;However, the data point we are receiving on Wednesday is only a tiny bit lower than the previous month, which is why there are shallow expectations that Bitcoin would make a significant move up or down based on this number.&#8221;
The report downplays the possibility of a major rally even if inflation comes in lower than expected. 
&#8220;We doubt that lower-than-expected inflation would set off a big rally,&#8221; they write. Their model suggests CPI will stay high for a few more months before dipping towards 3%.
&#8220;This would imply that Bitcoin could make a sizeable up-move on the back of lower-than-expected inflation by August, with the Fed then shifting back to verbally confirming rate cuts,&#8221; the report predicts. 
&#8220;Hence, we are still expecting a meaningful rally later in the year. Patience is the name of the game right now.&#8221;
In the immediate future, the report acknowledges headwinds for Bitcoin. &#8220;The market structure still appears to be a roadblock for any Bitcoin rally,&#8221; they write. 
Additionally, the SEC&#8217;s decision on a potential Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETF next week could further influence market sentiment.
&#8220;The best way to trade this week&#8217;s inflation data remains: if you are bullish, buy Bitcoin, bearish, short Ethereum,&#8221; concludes the report. 
&#8220;This week&#8217;s inflation print will likely not change this. We believe Bitcoin might see $52,000/$55,000 before a more meaningful rebound occurs.&#8221;
Looking For Deeper Insights Into The Future Of Digital Assets? 
Consider attending the Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
This gathering will bring together industry leaders to discuss the latest trends and<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38811221/this-ai-altcoins-predatory-tokenomics-will-fill-the-pockets-of-team-and-insiders-trader-wa"> innovations in this dynamic space.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38819008/dutch-court-sentences-tornado-cash-developer-to-64-months-for-money-laundering">Dutch Court Sentences Tornado Cash Developer To 64 Months For Money Laundering</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Inflation Data Means 'If You Are Bullish, Buy Bitcoin, Bearish, Short Ethereum': 10x Research

<div>With the benchmark diesel price used for most fuel surcharges down for the fifth week in a row, diesel consumers should be reveling in the fact that market trends appear to have completely thrown out concerns about the Middle East conflict and are focused on the markets for both diesel and gasoline as primary drivers.</div>

The Department of Energy/Energy Information Administration average weekly retail diesel price fell 4.6 cents Monday to $3.848 a gallon. The five consecutive declines have taken that price down 21.3 cents a gallon during, and the price is now at a level not seen since the end of January.

Whatever impact that oil markets may have felt from the conflict in Gaza, the Iran-Israel back-and-forth and the diversions of shipping away from the Red Sea (which may have faded from the news but continue) are apparently having no impact on oil prices. A reaction to those developments would tend to be macro in nature and would generally impact crude more than products.

But market weakness continues to show up in products markets, including diesel. And diesel in particular is getting a great deal of focus of late. <script type="text/javascript">
 window.googletag = window.googletag || {cmd: []};
 googletag.cmd.push(function() {
 googletag.defineSlot('/21776187881/FW-Responsive-Main_Content-Slot1', [[300, 100], [320, 50], [728, 90], [468, 60]], 'div-gpt-ad-1709668545404-0').defineSizeMapping(gptSizeMaps.banner1).addService(googletag.pubads());
 googletag.pubads().enableSingleRequest();
 googletag.pubads().collapseEmptyDivs();
 googletag.enableServices();
 });
</script>

<div>


<div id="div-gpt-ad-1709668545404-0"><script type="text/javascript">
 googletag.cmd.push(function() { googletag.display('div-gpt-ad-1709668545404-0'); });
 </script></div>
</div>

Diesel is increasingly being viewed as one of the primary reasons for the gradual fall in oil markets that has been occurring since early to mid-April. Whereas a few months ago, the rising price of oil was primarily attributed to a tight market for gasoline, the more recent weakness in oil overall is being laid firmly at the feet of the diesel market.

In his weekly report released Sunday, energy economist Philip Verleger noted that diesel weakness is becoming more structural because of the growing role of renewable diesel, which is made not from petroleum but from feedstocks such as plant oils and animal fats, including those captured in grease traps at restaurants.

In the report, Verleger noted that weekly EIA data on distillate consumption in the U.S., which is about 90% diesel, has been running anywhere from 400,000 to 600,000 barrels per day less than pre-pandemic levels. While some analysts are looking at that and concluding it is the function of a slow trucking market, Verleger's report cited the fact that the data isn't capturing the consumption of renewable diesel. 

"Taxes and regulations promulgated by the US Environmental Protection Agency have prompted refiners to convert crude oil processing facilities to produce renewable diesel, making more renewable fuel available" Verleger wrote. "The higher renewable diesel use will cut US petroleum consumption. At this juncture, it seems that none of the … most-quoted forecasts of global oil demand have been adjusted to account for this replacement." <script type="text/javascript">
 window.googletag = window.googletag || {cmd: []};
 googletag.cmd.push(function() {
 googletag.defineSlot('/21776187881/fw-responsive-main_content-slot2', [[468, 60], [728, 90], [300, 100], [320, 50]], 'div-gpt-ad-1665767472470-0').defineSizeMapping(gptSizeMaps.banner1).addService(googletag.pubads());
 googletag.pubads().enableSingleRequest();
 googletag.pubads().collapseEmptyDivs();
 googletag.enableServices();
 });
</script>

<div>


<div id="div-gpt-ad-1665767472470-0"><script type="text/javascript">
 googletag.cmd.push(function() { googletag.display('div-gpt-ad-1665767472470-0'); });
 </script></div>
</div>

Refining company earnings calls with analysts often feature management discussion of renewable diesel and its impact on the refiners' bottom line. For example, on the latest Phillips 66 call, CEO Mark Lashier reviewed the company's expanding renewable diesel operations and said that as a result of them, "we have gained valuable operational experience and market knowledge that positions us for success in our expanding renewable fuels business."

But on the latest round of calls, talk about the weak diesel market — its crack spread against Brent crude is down about 20 cents a gallon in two months — did arise. 

The view that diesel demand is weak was rejected by Gary Simmons, the executive vice president and chief operating officer at Valero (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vlo#NYSE">VLO</a>). He said on the company's first-quarter earnings calls that diesel sales at Valero are about 2% higher than those of a year ago. 

<div>
<script type="text/javascript">
 window.googletag = window.googletag || {cmd: []};
 googletag.cmd.push(function() {
 googletag.defineSlot('/21776187881/fw-responsive-main_content-slot3', [[728, 90], [468, 60], [320, 50], [300, 100]], 'div-gpt-ad-1665767553440-0').defineSizeMapping(gptSizeMaps.banner1).addService(googletag.pubads());
 googletag.pubads().enableSingleRequest();
 googletag.pubads().collapseEmptyDivs();
 googletag.enableServices();
 });
</script>



<div id="div-gpt-ad-1665767553440-0"><script type="text/javascript">
 googletag.cmd.push(function() { googletag.display('div-gpt-ad-1665767553440-0'); });
 </script></div>
</div>

But he added that he expects diesel demand will be "flat to slightly down compared to last year." "However, some of the freight indices appear to be turning, and indicate we could start seeing better demand" Simmons said. 

Brian Mandell, executive vice president of marketing and commercial for Phillips 66 (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/psx#NYSE">PSX</a>) said on the company's call that even though Ukraine's attacks on Russian refining capacity have probably taken about 200,000 barrels per day of Russian diesel supplies off the market, diesel prices have been suppressed by the warm winter in the northeastern U.S. — where heating oil, a distillate, is heavily used for home warmth — and by refiners coming out of maintenance season strong.

But the result has been reduction in refinery operating rates in Europe and Asia because of refining margins for distillates, which he said are around breakeven.

The weak market for products relative to crude is most visible in the 3-2-1 crack spread, a basic indicator of refinery probability. It is calculated by taking the price of two barrels of gasoline plus one barrel of diesel, converting it to a price per barrel and subtracting the price of crude, either Brent or West Texas Intermediate.

The Brent 3-2-1 on Monday, based on CME prices, fell to close to $21 a barrel. Two months ago, in mid-March, it was approximately $29.

<div>
The post <a href="https://www.freightwaves.com/news/diesel-takes-another-hit-and-may-be-driving-down-broader-oil-market">Diesel takes another hit and may be driving down broader oil market</a> appeared first on <a href="https://www.freightwaves.com">FreightWaves</a>.
</div>

Diesel Takes Another Hit and May be Driving Down Broader Oil Market

SCPX

Scorpius Holdings shares are trading lower after the company priced a 60 million unit offering at $0.10 per unit.

Raymond James (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rjf#NYSE">RJF</a>) is set to enter into the lucrative private credit business. Through its Investment Banking (&quot;IB&quot;) division, the company has formed a strategic collaboration with Eldridge Industries and Raymond James Bank. Spearheading this expansion is Omer Masud, a seasoned credit industry expert appointed as the head of sponsor finance origination. 
The newly formed Raymond James Private Credit aims to cater private credit solutions to portfolio companies of private equity firms. Leveraging Raymond James&#39; robust IB platform, Raymond James Bank&#39;s lending prowess and Eldridge Industries&#39; asset management expertise, the venture is poised to strengthen relationships with leading PE firms, particularly in key sectors such as consumer, diversified industrials, healthcare and technology &amp; services. 
Jim Bunn, the president of Global Equities and Investment Banking at RJF, emphasized the significance of this move in solidifying ties with the private equity community, underlining the firm&#39;s commitment to enhancing PE relationships. Steve Raney, the chairman and CEO of Raymond James Bank, highlighted the institution&#39;s history of offering comprehensive lending programs and expressed enthusiasm about extending these capabilities further in collaboration with Eldridge Industries. 
Todd Boehly, the co-founder and CEO of Eldridge Industries, echoed the sentiment, affirming private credit as a premier asset class and expressing pride in supporting Raymond James&#39; foray into this domain. 
With Eldridge&#39;s substantial assets under management and Raymond James&#39; established market presence, the collaboration positions both entities for significant growth and underscores their shared commitment to delivering tailored financial solutions to PE clients. 
Over the past year, shares of this Zacks Rank #3 (Hold) company have jumped 45.2%, outperforming the industry&#39;s growth of 36.8%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b9/66663.jpg?v=360114640" /> 
Image Source: Zacks Investment Research
As Raymond James and Eldridge Industries embark on this venture, they join a burgeoning landscape of financial institutions tapping into the vast potential of the private credit market. Several global firms like Goldman (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>) and Barclays (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>) are also venturing into this space, forming partnerships with investment firms to capitalize on the growing demand for alternative financing options. 
Last month, BCS made a push into the private credit market. The company, along with AGL Credit Management, announced a cooperation agreement and the launch of a private credit investment platform, AGL Private Credit. Likewise, this February, GS entered into a partnership with Mubadala Investment, an Abu Dhabi sovereign wealth fund, to invest $1 billion in private credit deals in multiple Asia-Pacific markets.
<a href="https://www.zacks.com/stock/news/2273313/raymond-james-rjf-forays-into-the-private-credit-business?cid=CS-BENZ-FT-analyst_blog|company_news_-_finance_sector-2273313">To read this article on Zacks.com click here.</a>

Raymond James Forays Into the Private Credit Business

FFIE

Faraday Future Intelligent Electric shares are trading higher, possibly amid strength in high-short interest stocks.

Politics

TikTok Creators Sue To Block U.S. Divest-Or-Ban Law

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bristol-Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) layoffs are a hot topic on Thursday after the biopharmaceutical&nbsp;company announced <a href="https://www.biopharmadive.com/news/bristol-myers-layoffs-restructuring-cost-savings/714254/#:~:text=Bristol%20Myers%20Squibb%20will%20cut,employees%2C%20the%20company%20said%20Thursday">major cuts are coming to its workforce</a>.



Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs. The company is expecting this will save it $1.5 billion per year by 2025.



These job cuts come after the company completed recent acquisition of Karuna and RayzeBio. It&rsquo;s also worth mentioning that Bristol-Myers Squibb&rsquo;s Q1 earnings report was released alongside the layoffs news. Investors were unimpressed by its results.



Bristol-Myers Squibb Chief Financial Officer David Elkins provided more details of the layoffs <a href="https://www.wsj.com/livecoverage/stock-market-today-earnings-04-25-2024/card/bristol-myers-squibb-to-cut-2-200-jobs-as-part-of-1-5-billion-cost-cutting-effort-7SscOv6dAdf0TrFvK4rN?siteid=yhoof2">during a conference call</a>. He notes that the headcount reductions are designed to make the company &ldquo;more agile,&rdquo; and plans to remove &ldquo;layers of management so decisions get made more quickly.&rdquo;



<h2>Bristol-Myers Squibb Joins Layoffs Trend</h2>



Bristol-Myers Squibb is joining a long list that continues to grow of companies that are laying off employees recently. That includes several other major players in the pharmaceutical space.



The increase in layoffs comes alongside a tough economy for businesses. That includes high inflation and increased interest rates weighing on both companies and consumers.



BMY stock is down 7.9% as of Thursday morning.



There are more stock market stories worth reading about below!



All of the latest stock market news for Tuesday is available for investors! Among that is why stocks are down today, the latest news on OptiNose&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/optn-stock-quote/">OPTN</a>) stock and more. All of this info is available at the following links!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-are-stocks-down-today-april-25th/">Why Are Stocks Down Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-optinose-optn-stock-up-12-today/">Why Is OptiNose (OPTN) Stock Up 12% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/meta-platforms-stock-is-down-10-is-this-the-beginning-of-the-end/">Meta Platforms Stock Is Down 10%. Is This the Beginning of the End?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/bristol-myers-squibb-layoffs-2024-what-to-know-about-the-latest-bmy-job-cuts/">Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Longeveron (LGVN – Research Report), Optinose (OPTN ...

Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be ideal investments now. Keep reading... In the ever-evolving landscape of pharmaceutical sector, the ascent of Pharma 4.0 heralds a transformative era. Besides, the growing interest among investors in pharmaceutical stocks is highlighted by the impressive performance of the Invesco Dynamic Pharmaceuticals ETF (<a href="https://stocknews.com/stock/PJP/">PJP</a>), which has seen a substantial return of 12.9% over the past six months.
Given this perspective, investors could find value in exploring reputable pharmaceutical stocks ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>), Amneal Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/AMRX/">AMRX</a>), and OptiNose, Inc. (<a href="https://stocknews.com/stock/OPTN/">OPTN</a>), which currently trade below $20 and are quite undervalued than their industry peers.
Drug shortages in the U.S. have <a href="https://www.biospace.com/article/us-drug-shortages-reach-all-time-high-since-2001-report-/">reached unprecedented levels</a>, with the American Society of Health-System Pharmacists reporting 323 active shortages as of the end of the first quarter of 2024. This marks the highest number since tracking began in 2001. The rising demand for medications presents a significant growth opportunity for pharmaceutical companies.
Moreover, IQVIA reports that <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028">global medicine usage has increased</a> by 14% over the last five years, with a projected additional 12% rise by 2028. This surge is anticipated to elevate annual usage to 3.80 trillion defined daily doses.
On top of that, with the advent of Pharma 4.0, the pharmaceutical industry is witnessing transformative technologies. This includes the development of smart medicines and digital therapeutics, which integrate drugs with digital components, enabling real-time monitoring of dosage intake and release. The global pharma 4.0 market size is expected to reach $54.43 billion by 2031, exhibiting a <a href="https://www.coherentmarketinsights.com/industry-reports/global-pharma-4-0-market">CAGR of 18.3%</a>.
Riding on these positive waves, let's dive into the core of the top <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> stocks, kicking off with our third pick.
Stock #3: ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>)
With a market cap of $2.82 billion, ACAD is a pharma company that focuses on CNS disorder treatments. Its key product is NUPLAZID for Parkinson's disease psychosis. The company is also developing DAYBUE for Rett Syndrome and has several drugs in various trial phases for conditions like schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, Rett syndrome, and Fragile X syndrome.
In terms of forward EV/Sales, ACAD is trading at 2.46x, 25.1% lower than the industry average of 3.29x. The stock's forward Price/Sales multiple of 2.86 is 17.9% lower than the industry average of 3.48.
On April 22, 2024, ACAD received Priority Review from Health Canada for trofinetide, a treatment for Rett syndrome, a rare neurodevelopmental disorder.
During the fiscal fourth quarter that ended December 31, 2023, ACAD's total revenues increased 69.3% year-over-year to $231.04 million. Moreover, its income from operations came to $34.94 million, compared to a loss from operations of $46.06 million in the prior-year quarter. Its net income and EPS stood at $45.80 million and $0.28, compared to net loss and net loss per share of $41.73 million and $0.26, respectively.
For the fiscal year 2024, ACAD projects net product sales to range between $370 and $420 million for DAYBUE and between $560 and $590 million for NUPLAZID. Additionally, they anticipate research and development expenses to fall between $305 and $325 million.
Analysts project ACAD's revenue for the fiscal first quarter that ended March 2024 to increase 76.2% year-over-year to $208.75 million. Its EPS is expected to be $0.06 for the same quarter. The company surpassed consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock surged 2% intraday to close the last trading session at $17.05.
ACAD's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust prospects. The stock has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
ACAD has an A grade for Growth and a B for Value and Quality. Within the 161-stock <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, it is ranked #30.
To see additional POWR Ratings for Momentum, Stability, and Sentiment for ACAD, click <a href="https://stocknews.com/stock/ACAD/">here</a>.
Stock #2: Amneal Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/AMRX/">AMRX</a>)
AMRX develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: generics; specialty; and AvKARE. Its market capitalization is $1.89 billion.
In terms of forward EV/Sales, AMRX is trading at 1.75x, 46.6% lower than the industry average of 3.29x. The stock's forward Price/Sales multiple of 0.72 is 79.4% lower than the industry average of 3.48.
On April 24, AMRX launched Over the Counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent to OTC NARCAN&#xAE; HCI Nasal Spray helps treat opioid drug overdose, including heroin, fentanyl, and prescription opioids. With a commitment to addressing public health emergencies, ARRX aims to make this emergency treatment accessible and affordable without a prescription.
On April 16, IMRX introduced PEMRYDI RTU&#xAE;, the first ready-to-use version of pemetrexed for injection, distinct from other formulations. This product streamlines administration by eliminating the need for reconstitution, dilution, or refrigeration, enhancing pharmacy efficiency and freeing up storage space.
With U.S. annual sales of pemetrexed reaching $287 million, AMRX's launch aims to provide a valuable solution for oncology care.
During the fiscal fourth quarter, which ended on December 31, 2023, AMRX's net revenue increased 1.2% year-over-year to $616.98 million and reported a gross profit of $189.83 million. The company reported <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> and net income of $142.15 million and $43.57 million, respectively. Also, it reported an adjusted EPS of $0.14 for the quarter.
As of December 31, 2023, the company's cash and cash equivalents stood at $91.54 million, compared to $25.98 million as of December 31, 2022.
For the fiscal year 2024, AMRX anticipates net revenue to range between $2.55 billion and $2.65 billion, with adjusted EBITDA projected to be in the range of $580 million to $620 million. In addition, the company's adjusted EPS is expected to fall between $0.53 and $0.63.
Street predicts AMRX's revenue for the first quarter (ended March 2024) to increase 11% year-over-year to $619.03 million, and its EPS for the same quarter is projected to come in at $0.09. Moreover, the company has an excellent earnings surprise history, surpassing consensus EPS estimates in each of the trailing four quarters.
Over the past nine months, shares of AMRX have surged 93.1% to close the last trading session at $6.12.
AMRX's shiny prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
AMRX has an A grade for Value and Sentiment and a B for Growth. It is ranked #24 in the same industry.
Beyond the POWR Ratings we've stated above, we also have AMRX ratings for Momentum, Quality, and Stability. Get all AMRX ratings <a href="https://stocknews.com/stock/AMRX/">here</a>.
Stock #1: OptiNose, Inc. (<a href="https://stocknews.com/stock/OPTN/">OPTN</a>)
OPTN is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It has a market cap of $102.31 million. The company provides XHANCE, a therapeutic product, and Onzetra Xsail, a powder EDS device.
OPTN's forward EV/Sales of 1.67x is 49.2% lower than the industry average of 3.29x. The stock's forward Price/Sales multiple of 1.03 is 70.5% lower than the industry average of 3.48.
OPTN recently celebrated the FDA approval of its XHANCE&#xAE; (fluticasone propionate) nasal spray for treating chronic rhinosinusitis without nasal polyps in patients 18 years and older. With strategic initiatives like optimized sales alignment and collaborations with specialty pharmacies, the company anticipates XHANCE's revenue peak to exceed $300 million by 2025.
OPTN reported total revenues of $19.87 million in the fiscal first quarter that ended December 31, 2023. It reduced its total cost and expenses by 23.4% year-over-year to $22.38 million. As of December 31, 2023, the company had cash and cash equivalents of $73.70 million.
For the first quarter of 2024, OPTN anticipates XHANCE net revenues to reach around $13.0 million. The company's revenue is expected to rise 15.4% year-over-year to $13.67 million in the fiscal first quarter (ended March 2024). Its EPS is likely to rise 36.8% from the previous year's quarter. Also, the company topped the consensus revenue estimates in all four trailing quarters.
The stock rose 10.6% intraday, closing the last trading session at $0.91.
It is no surprise that the stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Growth, Value, Sentiment, and Quality. OPTN is ranked #18 within the same industry.
Click <a href="https://stocknews.com/stock/OPTN/">here</a> to access OPTN's additional grades for Stability and Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ACAD shares were unchanged in premarket trading Thursday. Year-to-date, ACAD has declined -45.54%, versus a 6.38% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/acad-amrx-optn-buy-alert-3-pharma-stocks-under-20-to-invest-in/>Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more... The pharmaceutical industry is experiencing steady growth due to surging healthcare demand worldwide, particularly with an aging population and the rising prevalence of chronic and rare diseases and regulatory initiatives. Moreover, pharma 4.0 is expected to bring about significant advancements and efficiencies in the industry.
Given the industry's promising prospects, investors could consider snatching up fundamentally sound pharma stocks Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>), Spero Therapeutics, Inc. (<a href="https://stocknews.com/stock/SPRO/">SPRO</a>), and OptiNose, Inc. (<a href="https://stocknews.com/stock/OPTN/">OPTN</a>) for steady gains during market dips.
Breakthrough therapies launched over the last decade have reshaped patient care in several areas and positively impacted the outlook for medicine use and related spending. Advances in genomics, targeted therapies, and personalized medicine has enabled more precise and effective treatments tailored to individual patient's disease characteristics.
Over the past five years, medicine use globally rose by 14%, and a <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028">further increase of 12%</a> is anticipated through 2028, resulting in an annual use of 3.8 trillion defined daily doses. Meanwhile, world medicine spending surged by 35% over the past five years and is expected to grow by 38% through 2028.
Furthermore, the emerging field of Pharma 4.0 provides innovative technologies, including automation, artificial intelligence (AI), and data analytics for pharmaceutical manufacturing, R&amp;D, supply chain management, and healthcare delivery, potentially transforming the industry. The global pharma 4.0 market is expected to reach $54.43 billion by 2031, growing at <a href="https://www.coherentmarketinsights.com/industry-reports/global-pharma-4-0-market#:~:text=The%20global%20pharma%204.0%20market,to%20transform%20the%20pharmaceutical%20industry.">a CAGR of 18.3%</a>.
Also, investors' interest in pharma stocks is evident from the Vanguard Health Care ETF's (<a href="https://stocknews.com/stock/VHT/">VHT</a>) 11.9% returns over the past six months.
Given the encouraging market trends, let's look at the fundamentals of the best <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> stocks, beginning with the third choice.
Stock #3: Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>)
BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products globally. The company provides products for hematology, oncology, immunology, cardiovascular, fibrotic, and neuroscience diseases. Its products include Eliquis, Pomalyst/Imnovid, Orencia, Empliciti, and Sprycel.
BMY's forward EV/EBITDA of 7.54x is 49.4% lower than the industry average of 12.82x. Also, the stock's forward Price/Sales of 1.95x is 45.9% lower than the industry average of 3.60x. Its forward Price/Cash Flow multiple of 4.92 is 68.2% lower than the industry average of 15.46.
On May 1, 2024, BMY and Editas Medicine, Inc. (<a href="https://stocknews.com/stock/EDIT/">EDIT</a>), a clinical-stage gene editing company, announced a two-year extension to their partnership under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for treating cancer and autoimmune diseases.
Under the collaboration, BMY had opted into 13 distant programs across 11 gene targets.
On April 29, BMY entered a multi-year strategic collaboration with Repertoire&#xAE; Immune Medicines, a biotech company pioneering the discovery and development of programmable T-cell targeted immune medicines to develop tolerizing vaccines for up to three autoimmune diseases.
The partnership aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system, reflecting a key component of Bristol's immunology research strategy.
During the first quarter that ended March 31, 2024, BMY's total revenues increased 4.7% year-over-year to $11.87 billion, and its net product sales were $1156 billion, up 4.6% from the prior year's quarter. Its gross profit rose 1.8% year-over-year to $8.93 billion. In addition, the company's <a href="https://www.investopedia.com/terms/c/cashandcashequivalents.asp">cash and cash equivalents</a> were $9.33 billion as of March 31, 2024.
Analysts expect BMY's revenue for the second quarter (ending December 2024) to increase 2.4% year-over-year to $11.50 billion. Similarly, its revenue is expected to grow 2.3% year-over-year to $46.02 billion. Furthermore, the company has surpassed the consensus EPS estimates in three of the trailing four quarters.
BMY's stock has declined 3.6% over the past five days to close the last trading session at $43.70.
BMY's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
BMY has a B grade for Value and Growth. It is ranked #22 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
In addition to the POWR Ratings stated above, one can access BMY's ratings for Quality, Stability, Sentiment, and Momentum <a href="https://stocknews.com/stock/BMY/">here</a>.
Stock #2: Spero Therapeutics, Inc. (<a href="https://stocknews.com/stock/SPRO/">SPRO</a>)
SPRO is a multi-asset clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), SPR206, and SPR720.
In terms of forward EV/Sales, SPRO is trading at 0.26x, 92.4% lower than the industry average of 3.40x. Likewise, the stock's forward EV/Sales of 1.73x is 52% lower than the industry average of 3.60x.
On February 28, SPRO received clearance from the FDA for its investigational new drug (IND) application to evaluate SPR206 in a Phase 2 clinical study. SPR206 is a novel, intravenously (IV) administered polymyxin antibiotic for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
SPR206 is being developed to address high unmet need areas, and if approved, it will provide clinicians with a valuable new therapeutic option.
SPRO's collaboration revenue-related party for the fourth quarter that ended December 31, 2023, increased 55.4% year-over-year to $71.60 million. Its total revenue was $73.52 million, up 55% from the previous year's period. Also, as of December 31, 2023, its total assets stood at $182.39 million, compared to $124.80 million as of December 31, 2022.
Street expects SPRO's revenue to increase 940.8% year-over-year to $21.53 million for the first quarter that ended March 2024. The company's EPS grew 82.7% year-over-year for the same period. Moreover, SPRO has topped the consensus revenue estimates in each of the trailing four quarters.
Shares of SPRO have gained 11.7% over the past three months and 41.2% over the past six months to close the last trading session at $1.61.
SPRO's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
SPRO has an A grade for Value and a B for Quality and Sentiment. It is ranked #20 among 161 stocks in the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/SPRO/">Click here</a> to access the additional POWR Ratings for Growth, Stability, and Momentum for SPRO.
Stock #1: OptiNose, Inc. (<a href="https://stocknews.com/stock/OPTN/">OPTN</a>)
OPTN operates as a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, throat (ENT) and allergy specialists. The company offers XHANCE, a therapeutic product, and Onzetra Xsail, a powder EDS device.
OPTN's forward EV/Sales of 1.78x is 47.7% lower than the industry average of 3.40x. Also, the stock's forward Price/Sales of 1.13x is 68.5% lower than the industry average of 3.60x.
On March 16, OPTN announced that the FDA approved its XHANCE&#xAE; (fluticasone propionate) nasal spray for treating chronic rhinosinusitis without nasal polyps in patients 18 years and older. This FDA approval of XHANCE, as the first and only approved drug treatment for chronic sinusitis (CS), is a landmark achievement for the company.
OPTN announced preliminary XHANCE net product revenue of $14.90 million for the first quarter that ended March 31, 2024, indicating growth of around 26% from the prior year's quarter. Further, for the fiscal year 2025, the company expects peak XHANCE net revenues to surpass $300 million. It is also expected to produce positive income from operations for the full year.
For the fourth quarter that ended December 31, 2023, OPTN reported total revenues of $19.87 million. Its total cost and expenses decreased by 23.4% year-over-year to $22.38 million. Additionally, as of December 31, 2023, the company's cash and cash equivalents came in at $73.68 million.
Analysts expect OPTN's revenue for the fiscal year 2024 to increase 27.4% year-over-year to $90.46 million. The consensus revenue estimate of $130.22 million for the fiscal year 2025 indicates an improvement of 43.9% year-over-year. In addition, the company surpassed the consensus revenue estimates in all four trailing quarters.
OPTN's stock surged 4.4% over the past five days to close the last trading session at $0.88.
OPTN's POWR ratings reflect bright prospects. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Growth, Value, Sentiment, and Quality. OPTN is ranked #17 in the same industry.
<a href="https://stocknews.com/stock/OPTN/">Click here</a> to access OPTN's additional grades for Stability and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
OPTN shares rose $0.00 (+0.03%) in premarket trading Friday. Year-to-date, OPTN has declined -31.78%, versus a 6.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/optn-bmy-spro-edit-3-pharma-stocks-to-snatch-up-during-market-dips/>3 Pharma Stocks to Snatch up During Market Dips</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharma Stocks to Snatch up During Market Dips

CRVS, CTMX and NRXP are among premarket  gainers

Optinose Inc (OPTN) just unveiled an announcement. OptiNose, Inc. has initiated a Registered Direct Offering, agreeing to sell over 31 million comm...

OptiNose Inc Raises $55 Million to Boost XHANCE Commercialization

DTCK, NCI and SLNH among pre-market losers

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Optinose (OPTN – Research Report). The company's shares close...

Lake Street Reaffirms Their Buy Rating on Optinose (OPTN)

Optinose GAAP EPS of -$0.12, revenue of $14.88M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OptiNose (NASDAQ:<a href="https://investorplace.com/stock-quotes/optn-stock-quote/">OPTN</a>) just reported results for the first quarter of 2024.<ul><li>OptiNose reported earnings per share of -12 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company reported revenue of $14.88 million.</li><li>This was 14.99% better than the analyst estimate for revenue of $12.94 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/optn-stock-earnings-optinose-for-q1-of-2024/">OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024

ABNB

ACAD

AKBA

ALGM

AMRX

ATNM

BENF

CDLX

CMPO

CRNC

CTMX

DTCK

DUOL

EDIT

EMKR

EPAM

FWRD

GDRX

IHRT

IMTE

INCR

LGVN

NITO

NUVO

PLUG

RBLX

SLNH

SPRO

SYRA

TIVC

VTNR

ZVSA

Press Releases

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Opinion

Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps